For people with innately acne-prone skin, certain topical treatments and medications help minimize breakouts for the most part
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,813 followers
En el estudio de resultados cardiovasculares LEADER, se sigui durante una media de 3.8 aos a 9340 pacientes con DM2 mayores de 50 aos con al menos una condicin cardiovascular (CV), incluida la ERC (definida como una TFGe 60 ml/min/1.73 m 2 (HR: 0.69
In recent years, the impact of diabetes on spermatogenesis has emerged as a research focus, with numerous studies revealing its adverse effects on sperm quality, motility, and morphology through pathways including oxidative stress, endoplasmic reticulum(ER) stress, endocrine disruption, and microcirculatory impairment
